Email this article SEQUENTIAL USE OF TARGET AGENTS AND THEIR COMBINATION IN THE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA
- Authors: Alekseyev B.Y.1, Kalpinsky A.S.1
-
Affiliations:
- P.A. Herzen Moscow Research Oncological Institute, Russian Agency for Medical Technologies
- Issue: Vol 6, No 4 (2010)
- Pages: 16-22
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
- Published: 30.12.2010
- URL: https://oncourology.abvpress.ru/oncur/article/view/325
- DOI: https://doi.org/10.17650/1726-9776-2010-6-4-16-22
- ID: 325
Cite item
Full Text
Abstract
The development of molecular biology led to the discovery of major pathogenetic pathways in the development of renal cell carcinoma (RCC), contributing to the designing of novel drugs to treat metastatic RCC, which belong to a group of target agents or tyrosine kinase inhibitors. Phases II and III clinical trials have proven the efficacy and controlled safety profile of a broad range of drugs for the treatment of metastatic RCC. The developing resistance to drugs and their intolerance determine the need to conduct new clinical studies and to search for novel agents and treatment regimens to improve survival and quality of life in patients. The performed studies of the efficiency and safety of sequential use of antiangiogenic drugs and their combination have supported that it is expedient to apply these treatment policies to patients with metastatic RCC. The expected results from the ongoing large Phase III clinical trials will let one find out how to optimally use target agents, in what combination or in what sequence.
About the authors
B. Ya. Alekseyev
P.A. Herzen Moscow Research Oncological Institute, Russian Agency for Medical Technologies
Author for correspondence.
Email: byalekseev@mail.ru
Russian Federation
A. S. Kalpinsky
P.A. Herzen Moscow Research Oncological Institute, Russian Agency for Medical Technologies
Email: byalekseev@mail.ru
Russian Federation
References
Supplementary files
